Table 1 Clinical characteristics
|  | Obesity (n = 427) | Non-obesity (n = 698) | P |
|---|---|---|---|
Age, years | 63 ± 10 | 66 ± 10 | <0.001 |
Male | 283 (66) | 457 (66) | 0.783 |
BMI, kg/m2 | 27.1 ± 2.0 | 22.3 ± 1.8 | <0.001 |
Co-existing conditions | |||
 Hypertension | 294 (69) | 448 (64) | 0.109 |
 Dyslipidemia | 134 (31) | 169 (24) | 0.009 |
 CKD | 110 (26) | 232 (33) | 0.008 |
 Previous MI | 22 (5) | 39 (6) | 0.754 |
Smoking | 143 (34) | 229 (33) | 0.814 |
STEMI | 204 (48) | 326 (47) | 0.727 |
LVEF | 53 ± 11 | 50 ± 12 | <0.001 |
Systolic blood pressure, mmHg | 130 ± 28 | 130 ± 28 | 0.851 |
Diastolic blood pressure, mmHg | 78 ± 17 | 76 ± 16 | 0.116 |
eGFR, mL/min/1.73 m2 | 76 ± 29 | 72 ± 33 | 0.105 |
DM duration, years | 9.8 ± 8.2 | 11.5 ± 8.5 | 0.003 |
Laboratory | |||
 Total cholesterol, mg/dL | 178 ± 46 | 170 ± 46 | 0.004 |
 Triglyceride, mg/dL | 146 ± 98 | 131 ± 100 | 0.022 |
 LDL, mg/dL | 109 ± 40 | 101 ± 41 | 0.002 |
 HDL, mg/dL | 44 ± 28 | 44 ± 17 | 0.988 |
 Creatinine, mg/dL | 1.2 ± 1.3 | 1.3 ± 1.4 | 0.130 |
 HbA1c, % | 7.8 ± 1.4 | 7.9 ± 1.6 | 0.370 |
 hs-CRP, mg/dL | 4.6 ± 15.9 | 6.9 ± 23.9 | 0.081 |
 NT-ProBNP, pg/mL | 2836 ± 7592 | 4040 ± 9074 | 0.096 |
 Peak CK-MB, ng/mL | 82 ± 114 | 83 ± 137 | 0.880 |
 Troponin-I, ng/mL | 29 ± 62 | 31 ± 59 | 0.637 |
Medication at discharge, n (%) | |||
 Aspirin | 423 (99) | 683 (98) | 0.126 |
 Clopidogrel | 409 (96) | 661 (95) | 0.413 |
 Cilostazol | 83 (19) | 131 (19) | 0.781 |
 Beta blocker | 364 (85) | 591 (85) | 0.794 |
 ACEI/ARB | 355 (83) | 586 (84) | 0.720 |
 Statin | 365 (86) | 572 (82) | 0.123 |
 Nitrate | 111 (26) | 205 (29) | 0.222 |
 Nicorandil | 77 (18) | 149 (21) | 0.178 |
 Insulin | 51 (12) | 119 (17) | 0.020 |
2-year clinical outcomes, n (%) | |||
 Cardiac death | 3 (0.7) | 25 (3.6) | 0.003 |
 All-cause death | 8 (1.9) | 36 (5.2) | 0.006 |